Publications by authors named "Raghda Shetta"
Safety and efficacy of sparsentan versus irbesartan in focal segmental glomerulosclerosis and IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials.
Ahmed A Abo Elnaga Mohamed A Alsaied Abdelrahman M Elettreby Alaa Ramadan Mohamed Abouzid Raghda Shetta
BMC Nephrol
September 2024
Article Synopsis
- Sparsentan has shown positive results in treating IgA nephropathy and focal glomerulosclerosis (FSGS), but a pooled analysis of recent trials is needed to confirm its efficacy and safety compared to irbesartan.
- A systematic review of three studies involving 884 patients found that sparsentan significantly improves proteinuria levels and remission rates, but both medications have similar effects on kidney function.
- Although sparsentan is generally effective and safe, it does have a higher incidence of hypotension, and further research with larger sample sizes is necessary for more definitive conclusions.